JPRN-jRCTs061220050
Recruiting
Phase 2
Improvement effect and safety of overactive bladder symptoms by 5-aminolevulinic acid (5-ALA) intake;Double-blind randomized placebo-controlled trial
Fukata Satoshi0 sites100 target enrollmentAugust 29, 2022
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Overactive bladder
- Sponsor
- Fukata Satoshi
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All of the following criteria must be met in order to
- •participate in this trial.
- •1\.Patients with overactive bladder over 30 years
- •2\.Patients with overactive bladder who consented
- •to participate in the study in writing
Exclusion Criteria
- •If any of the following criteria are met, the patient
- •will not be allowed to participate in this trial.
- •1\.Patients with organic disease of the urinary tract
- •2\.Patients with neurogenic overactive bladder
- •3\.Patients with malignant tumors of the urinary sys
- •4\.Patients with cognitive dysfunction or psychiatri
- •c disorders that are difficult to conduct research
- •5\.Patients who are allergic to 5\-ALA
- •6\.Patients with porphyria
- •7\.Patients with drug hypersensitivity such as iron a
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Examination of the effect of overactive bladder treatment on female sexual functiooveractive bladderJPRN-UMIN000043168Sapporo Medical University100
Not yet recruiting
Phase 4
Defining the Safety and Efficacy of POSterIor Tibial NeRve StimulatiON in ChildrenOveractive BladderOveractive Bladder SyndromeNCT06769854Chi Dang Hornik50
Not yet recruiting
Not Applicable
comparison between a bladder sparing approach and a radical cystectomy in patients with a non-metastasized muscle invasive bladder carcinomablaaskanker, spierinvasiefbladder cancer, muscle invasiveNL-OMON25055Amsterdam UMC, AMC1,000
Active, not recruiting
Phase 2
Bladder Preservation Therapy in combination with Atezolizumab and Radiation Therapy for invasive bladder cancer, a phase II, open-label, multicenter studyBladder cancerJPRN-jRCT2031180060ishiyama Hiroyuki45
Completed
Phase 4
Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress IncontinenceUrinary Bladder, OveractiveNCT01194999Barrie Urology Associates132